| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df874e3cf88adba3792dc9d5b5776180 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T2207-30096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T2207-10072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T2207-10104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T2207-10081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T2207-10088 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-5217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T7-0012
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H30-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H30-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H30-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06T7-00 |
| filingDate |
2018-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf9c4d93bf06fbdbc522459ab2fbcf3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f028b03b5db6c675d236f655750442f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06f3893e773b17f48b8bb191b8aa4d2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d17d47234946ea30dc7cf12ac495618 |
| publicationDate |
2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3652534-A1 |
| titleOfInvention |
A radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-pd-1/pd-l1 |
| abstract |
The present invention provides a radiomic-based biomarker for detecting the presence and density of infiltrated CD8 T cells in solid tumors without having to use a biopsy of said tumor. The invention also proposes to use this information to evaluate the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to predict the survival and / or treatment efficacy of cancer patients treated with immunotherapy such as monotherapy with anti-PD-1 / PD-L1 agent. |
| priorityDate |
2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |